MELBOURNE, Australia and INDIANAPOLIS, Ind. — October 6, 2026
Telix Pharmaceuticals Limited announced that the first U.S. patients have been dosed with Pixclara® (floretyrosine F 18), marking the start of commercial availability for the company’s FDA-approved PET imaging drug for glioma. The first doses were administered at Indiana University Health Neuroscience Center in Indianapolis and University Hospitals Cleveland Medical Center in Cleveland, Ohio. The milestone represents the transition of Pixclara from regulatory approval to commercial clinical availability in the United States. Telix said its U.S. manufacturing and pharmacy distribution partner, PharmaLogic Holdings Corp., is supplying finished unit doses to healthcare providers across the U.S. market. Pixclara is indicated for use with positron emission tomography (PET), in conjunction with other diagnostic evaluations, to help differentiate recurrent or progressive glioma from treatment-related change in adult and pediatric patients one month of age and older.
Pixclara Addresses Key Glioma Imaging Challenge
Pixclara is the only FDA-approved radiopharmaceutical imaging drug specifically approved for glioma imaging in the United States, according to Telix. The commercial availability of the product is intended to address an important diagnostic challenge in neuro-oncology, where physicians may need to distinguish active or recurrent disease from changes caused by previous treatment. This distinction can influence subsequent clinical decision-making and treatment planning for patients with brain cancer. Pixclara uses floretyrosine labeled with fluorine-18 (18F-FET) as a PET imaging agent. Following intravenous administration, the compound targets L-type amino acid transporters LAT1 and LAT2, allowing the radioactive signal to be detected using PET imaging. Telix said the availability of an FDA-approved commercial FET-PET option could help expand access to this imaging approach for U.S. patients with glioma and provide clinicians with an additional diagnostic tool alongside existing evaluations.
Telix Expands Precision Imaging Access in U.S.
The first commercial doses represent a significant operational milestone for Telix’s precision medicine strategy and its U.S. radiopharmaceutical business. The company is supporting distribution through PharmaLogic while establishing Pixclara as a commercially available diagnostic option for neuro-oncology centers. Clinicians at the initial treatment sites highlighted the potential importance of having an FDA-approved and commercially accessible FET-PET imaging option for patients with glioma. Telix also noted that FET-PET imaging is included in international clinical practice recommendations, including NCCN Guidelines, further supporting the company’s efforts to translate the established imaging approach into broader U.S. clinical access. Beyond its current indication, Pixclara, also known as TLX101-Px, is being evaluated in a Phase 3 registrational study for a potential expanded indication involving the diagnosis of brain metastases. The U.S. commercial launch therefore establishes a foundation for Telix’s broader development and commercialization strategy in molecular imaging and precision diagnostics.
Advertisement
Pixclara Advances Telix’s Neuro-Oncology Pipeline
Gliomas represent a major unmet need in central nervous system oncology, with gliomas accounting for a substantial proportion of malignant brain tumors. Telix is positioning Pixclara as an important diagnostic component within the neuro-oncology care pathway by providing PET-based information that may help clinicians evaluate suspected recurrent or progressive disease. The product’s approval for adults and pediatric patients one month of age and older also gives Telix access to a broad patient population within the approved glioma indication. With the first commercial doses now administered in Indianapolis and Cleveland, Pixclara has entered its U.S. commercial phase, supported by Telix’s manufacturing and distribution network. The milestone strengthens Telix’s position in radiopharmaceutical imaging and precision medicine while creating a commercial platform for potential future applications of floretyrosine F 18 in brain cancer imaging. The launch marks an important step in bringing FDA-approved FET-PET imaging into routine U.S. clinical availability for glioma patients.
Source:: Telix Pharmaceuticals, press release
